Congress funds coordinated Down syndrome research, expands clinical trials

What it does

This bill authorizes the National Institutes of Health (NIH) to establish and carry out a coordinated research program on Down syndrome, called the INCLUDE Project, focusing on understanding how trisomy 21 affects development and health across the lifespan, improving clinical trials for people with Down syndrome, studying co-occurring conditions like Alzheimer's disease and autoimmunity, and enhancing quality of life. The bill requires the NIH Director to coordinate research across all NIH institutes and centers, consult with patient advocates, and report biennial progress to Congress.

Why we flagged it

The bill's core mechanism is a straightforward authorization for NIH to conduct and coordinate Down syndrome research. It is a public-health research mandate with no deregulation, subsidy, or private carve-out.

What the text implies

• The bill does not appropriate funds — it only authorizes the NIH Director to carry out the program. Actual funding depends on future congressional appropriations, meaning the program's scope and timeline remain uncertain.
• Requirement to consult with patient advocates and stakeholders may elevate the voice of people with Down syndrome in research priority-setting, potentially shifting research focus away from rare or commercially uninteresting co-occurring conditions toward those with broader patient demand.
• Biennial reporting requirement creates a public accountability mechanism, but reports are submitted only to congressional committees, not published for general public access unless separately released.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill establishes a dedicated, coordinated research program addressing a significant gap in medical knowledge about Down syndrome and co-occurring conditions, with explicit requirements for stakeholder consultation and transparency through biennial reporting. People with Down syndrome and their families gain from expanded clinical trial access, improved diagnosis and treatment of related conditions, and research aimed directly at quality of life.

Who stands to gain

• pharmaceutical companies (through expanded clinical trial participation and drug development opportu
• biomedical research institutions and universities (through NIH research grants and contracts)
• diagnostic and therapeutic device manufacturers (through research on biomarkers and interventions)

Named in the bill

National Institutes of Health (NIH), NIH Director, Office of the Director of NIH, House Committee on Energy and Commerce, House Committee on Appropriations (Labor, Health and Human Services subcommittee), Senate Committee on Health, Education, Labor, and Pensions, Senate Committee on Appropriations (Labor, Health and Human Services subcommittee), Down syndrome patient advocates, Pharmaceutical companies (BMY, GH, PFE, JNJ, DVA)

Where it stands

18 cosponsors: 12 Democrats, 6 Republicans.

• May 19, 2025 — Introduced · Congress.gov: “Introduced in House”
• May 19, 2025 — Referred to House Committee on Energy and Commerce and Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Referred to the House Committee on Energy and Commerce”
• May 21, 2026 — Markup held in committee · Congress.gov: “Committee Consideration and Mark-up Session Held”
• May 21, 2026 — Reported out of committee · Congress.gov: “Ordered to be Reported by the Yeas and Nays: 46 - 0”
• Jul 20, 2026 — Passed the House · Congress.gov: “On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H4649-4650)”
• Jul 20, 2026 — Floor vote scheduled · Congress.gov: “Mr. Guthrie moved to suspend the rules and pass the bill”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 3 disclosure filings across 2 quarters, Jun 2025 to Jun 2026. Those filings disclosed $3,590,000 in lobbying spend. A filing names 26 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Diana DeGette, the sponsor, reported $915,500 in PAC receipts in the 2026 cycle.

• Alzheimer's Association — $3,590,000 on 2 filings
• Global Down Syndrome Foundation — $0 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.